Kennedy Capital Management LLC Buys 26,216 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Kennedy Capital Management LLC lifted its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 17.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 172,931 shares of the company’s stock after purchasing an additional 26,216 shares during the quarter. Kennedy Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $6,066,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in NAMS. Capital World Investors raised its stake in shares of NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the period. Duquesne Family Office LLC raised its stake in shares of NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after buying an additional 1,091,525 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after buying an additional 1,062,359 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of NewAmsterdam Pharma by 96.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,725,662 shares of the company’s stock worth $60,536,000 after buying an additional 845,110 shares during the period. Finally, Wellington Management Group LLP raised its stake in shares of NewAmsterdam Pharma by 21.0% in the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after buying an additional 697,129 shares during the period. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Up 0.7%

Shares of NAMS opened at $30.60 on Tuesday. The business’s 50 day moving average is $33.39 and its 200 day moving average is $33.58. The company has a market capitalization of $3.58 billion, a PE ratio of -17.09 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 12-month low of $17.63 and a 12-month high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The business had revenue of $3.04 million for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. Equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 65,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $35.69, for a total value of $2,319,850.00. Following the sale, the chief accounting officer owned 24,353 shares of the company’s stock, valued at $869,158.57. The trade was a 72.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.74% of the stock is currently owned by insiders.

Analyst Ratings Changes

NAMS has been the topic of several recent analyst reports. Guggenheim lifted their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Needham & Company LLC lifted their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Tuesday, April 21st. Finally, HC Wainwright raised NewAmsterdam Pharma to a “strong-buy” rating in a research note on Thursday, February 19th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $48.60.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.